Genmab — Marts 2017
-
Appologies for the strong language

-
@ Mscotland. Kyprolis (carfilzomib) er en protesomhæmmer ligesom Velcade (bortezomib). Disse to var sat op imod hinanden i et fase 3 studie, som faldt ud til Kyprolis' fordel http://wwwext.amgen.com/media/news-releases/2017/02/phase-3-headtohead-trial-showed-kyprolis-carfilzomib-significantly-improved-overall-survival-compared-to-velcade-bortezomib-in-relapsed-or-refractory-multiple-myeloma-patients/ . Heldigvis for det, for det betyder at kombinationen med dara og en proteasomhæmmer blot bliver
-
-
haha
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind